直到现在,对于先天性胆道扩张(CBD)尚无实用的临床指南.在这篇评论文章中,日本先天性胆道扩张研究小组(JSCBD)建议建立CBD的临床实践指南。因为基于证据的文献相对较少,我们决定根据专家的共识制定指导方针,使用医学文献作为参考。负责指南的编辑委员会成员总共考虑了20个临床问题(CQs)。CQ包括CBD的不同方面:(1)概念和病理学(三个CQ);(2)诊断(六个CQ);(3)胰胆管并发症(三个CQ);治疗和预后(八个CQ)。CQ的每个陈述和评论均由准则委员会成员做出。CQ在由CBD编辑委员会和指南评估委员会成员审查后最终获得批准。创建这些指南是为了在CBD管理的临床实践中提供帮助;他们的内容侧重于临床效用,它们包括有关CBD的一般信息,以使这种疾病得到更广泛的认可。
Until now, there have been no practical clinical
guidelines for congenital biliary dilatation (CBD). In this review article, the Japanese Study Group on Congenital Biliary Dilatation (JSCBD) propose to establish clinical practice guidelines for CBD. Because the evidence-based literature is relatively small, we decided to create
guidelines based on the
consensus of experts, using the medical literature for reference. A total of 20 clinical questions (CQs) were considered by the members of the editorial committee responsible for the guidelines. The CQs included the distinct aspects of CBD: (1) Concepts and Pathology (three CQs); (2) Diagnosis (six CQs); (3) Pancreaticobiliary Complications (three CQs); Treatments and Prognosis (eight CQs). Each statements and comments for CQs were made by the
guidelines committee members. CQs were finally approved after review by members of the editorial committee and the guidelines evaluation board of CBD. These
guidelines were created to provide assistance in the clinical practice of CBD management; their contents focus on clinical utility, and they include general information on CBD to make this disease more widely recognized.